Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775657 | 0.89 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E | |
| SCHEMBL5772744 | 0.88 | ALOX5 (0.50) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E | |
| SCHEMBL5773864 | 0.85 | MAPT (0.50) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E | |
| SCHEMBL2748256 | 0.82 | LMNA (0.54) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E | |
| SCHEMBL5771719 | 0.82 | SLC6A2 (0.48) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E | |
| SCHEMBL5774019 | 0.81 | MAPT (0.54) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E | |
| SCHEMBL21264058 | 0.81 | MAPT (0.54) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E | |
| SCHEMBL5771002 | 0.81 | GCGR (0.55) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E | |
| SCHEMBL2748270 | 0.80 | HPGD (0.56) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E | |
| SCHEMBL1681378 | 0.78 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934535-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2934535-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9637493-B2 | Substituted pyrrolopyrimidines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637493-B2 | Substituted pyrrolopyrimidines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637493-B2 | Substituted pyrrolopyrimidines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150329548-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329548-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329548-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2934535-A2 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014100071-A2 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100071-A2 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-1054887-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-6583154-B1 | Neuropeptide Y antagonist; pyrrolo-(3,2-b)pyridines and pyrrolo-(3,2-d)pyrimidines | AMGEN INC. | 2003-06-24 | — | — | US | disclosed |
| US-6187777-B1 | PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES; NEUROPEPTIDE Y AND CORTICOTROPIN RELEASING FACTOR MODULATORS; DIETETICS; ANTIDIABETIC, ANTIINFLAMMATORY, AND ANTITUMOR AGENTS | AMGEN INC. | 2001-02-13 | — | — | US | disclosed |
| EP-1054887-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999040091-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329548-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | PHLPP2, DDX21, TP53 | ALDH1A1 2444/4885SMN1; SMN2 2008/4885MAPT 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.